Israel Active

Israel’s Isotopia Molecular Imaging has entered into a development partnership with Germany’s Eckert & Ziegler for the development of its PSMA-11-Kit for prostate cancer imaging. Isotopia’s team includes some of Israel’s leading scientists.

Israeli scientists are frequently finding new ways of personalizing cancer treatments. Some are based on genetics or proteins expressed by the body . Now Weizmann Institute researchers are devising a system to predict how patients will respond to immunotherapy.

Israel’s MDClone organizes patient data to help medical research in Israel and in the US.  It has now expanded to Canada with The Ottawa Hospital – one of Canada’s largest hospitals. MDClone’s technology can potentially benefit thousands of Canadians.

Doctors at Jerusalem’s Alyn hospital developed Coughsync some 10 years ago to help relieve lung congestion in physically challenged and disabled children. Now it is being mass-produced to help clear secretions from the lungs of Chinese coronavirus patients on ventilators.

Tel Aviv University researchers have developed customizable contact lenses that can correct deuteranomaly, a form of red-green colorblindness. Ultra-thin optical devices were incorporated into off-the-shelf contact lenses.

Newsweek magazine listed Israel’s Sheba Medical Center at Tel Hashomer as the world's ninth-best hospital, up one place from last year (). Newsweek highlighted Sheba’s groundbreaking research in cancer, cardiology, brain diseases, genetics plus its global collaborations.

Researchers led by Professor Lior Gepstein of Israel’s Technion Institute and Rambam Medical Center have generated heart cells from stem cells that can be either atrial (upper) or ventricular (lower) chamber cells. It has significant benefits for testing cardiac treatments.

Latest progress on the vaccine being developed by Israeli scientists at the Migal Research Institute in Kiryat Shmona on the border with Lebanon. Also, an article on how the vaccine works.

As reported previously, the Allocetra treatment from Israel’s Enlivex cures patients suffering severe sepsis. Allocetra is now being offered to governments for the thousands of coronavirus patients suffering sepsis-induced organ failure due to overactive immune responses.

Israel’s NeoTX uses Selective T cell Redirection (STR) technology to enlist a powerful immune response against tumors. Mutated bacteria are fused with monoclonal antibodies which target the tumor’s 5T4 antigen, alerting T-cells to kill the tumor.  NeoTX has just raised $45 million of funds.